← Back to Search

Fewer Botox Injections for Urinary Incontinence

N/A
Recruiting
Led By Monique J Vaughan, MD
Research Sponsored by University of Virginia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Females at least 21 years of age
English speaking
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial aims to see if using 5 Botox injection sites instead of 15-20 can provide relief of UUI symptoms. Hypothesis: 5-site protocol is as good as the standard.

Who is the study for?
This trial is for English-speaking women over 21 with urgency urinary incontinence, who have not had Botox injections for this condition before. They must be willing to possibly use a catheter and follow the study's procedures. Excluded are those with certain medical conditions, previous pelvic surgeries, or untreated UTIs.Check my eligibility
What is being tested?
The study aims to see if fewer Botox injection sites (5 instead of the standard 15-20) will be just as effective in reducing episodes of urgency urinary incontinence. Participants will receive an equal amount of Botox but at different numbers of injection sites.See study design
What are the potential side effects?
Potential side effects from Botox may include pain at the injection site, urinary tract infections, difficulty urinating, and possible need for temporary catheterization due to weakened bladder muscles.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a woman aged 21 or older.
Select...
I speak English.
Select...
I am seeking treatment for sudden urges to urinate that I cannot control.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Reducton of Urgency Urinary Incontinence episodes in standard of care versus modified treatment group
Secondary outcome measures
Complications rates in standard of care (15 injections) versus modified treatment (5 injections)
Quality of life improvement in standard of care (15 injections) versus modified treatment (5 injections)

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ExperimentalExperimental Treatment1 Intervention
Subjects in this arm will be administered the same amount of Botox in 5 injection sites.
Group II: ControlsActive Control1 Intervention
Subjects in this arm will be administered the standard injection site protocol (15 sites).

Find a Location

Who is running the clinical trial?

University of VirginiaLead Sponsor
759 Previous Clinical Trials
1,245,530 Total Patients Enrolled
1 Trials studying Urinary Incontinence
30 Patients Enrolled for Urinary Incontinence
Monique J Vaughan, MDPrincipal InvestigatorUniversity of Virginia

Media Library

Experimental Clinical Trial Eligibility Overview. Trial Name: NCT04731961 — N/A
Urinary Incontinence Research Study Groups: Experimental, Controls
Urinary Incontinence Clinical Trial 2023: Experimental Highlights & Side Effects. Trial Name: NCT04731961 — N/A
Experimental 2023 Treatment Timeline for Medical Study. Trial Name: NCT04731961 — N/A
~9 spots leftby Dec 2024